The Front Room — a clinical regulatory commons
RSS
← Back to The Docket
JUN 26 2026
APPROVED · 35 DAYS AGO

Viridian Therapeutics — Lumvoa (veligrotug-vvze) $VRDN

for Thyroid eye disease (active and chronic)

BLA

FDA approved Viridian's Lumvoa (veligrotug-vvze) — an anti-IGF-1R monoclonal antibody — for thyroid eye disease in adults. First TED therapy with a label covering both active (early inflammatory) and chronic (post-inflammatory fibrotic) stages of the disease. Supported by the THRIVE and THRIVE-2 pivotal trials — the largest pivotal trials ever conducted in TED.

About

Thyroid eye disease is an autoimmune condition that causes painful inflammation, swelling, and bulging of the eyes. Lumvoa is an antibody drug that blocks the IGF-1R receptor, a key driver of this inflammatory process. This mechanism may reduce the signs and symptoms of the disease across both its active and chronic stages.

Share LinkedIn X Bluesky